CBSNews.com
  August 21, 2002 01:08:04

Section Front • Section Front

E-mail This StoryE-mail This Story  Printable VersionPrintable Version

Judge: Paxil Ads 'Misleading'

August 20, 2002



 (AP)



The ruling comes about a year after a class-action lawsuit was filed on behalf of 35 patients who claimed they suffered withdrawal symptoms such as nausea, fever, and "electric zaps" to their bodies.


(AP) A federal judge ordered the maker of the popular anti-depressant Paxil to halt all television commercials nationwide that claim the drug is not habit forming.

The ruling against GlaxoSmithKline comes about a year after a class-action lawsuit was filed on behalf of 35 patients who claimed they suffered withdrawal symptoms such as nausea, fever, and "electric zaps" to their bodies.

U.S. District Judge Mariana Pfaelzer found that in other countries, labels on the drug warn of adverse reactions when use of the drug is discontinued.

The commercials were "misleading and created inaccurate expectations about the ease of withdrawal from the drug," Pfaelzer ruled Monday.

Company attorneys are appealing.

"The U.S. Food and Drug Administration — and not the courts — has the expertise and responsibility for reviewing and regulating pharmaceutical ads," David Stout, president of U.S. Pharmaceuticals at Paxil's producers, GlaxoSmithKline, said in a statement.

"The Paxil television ad was submitted for FDA review prior to use, and the agency raised no objections to the language at issue," Stout said.

The plaintiffs' lead attorney, Karen Barth, said GlaxoSmithKline changed its labeling on Dec. 14 but continued to run commercials and distribute brochures saying Paxil "may cause mild, usually temporary side effects in some individuals."

Plaintiffs' attorneys said a hearing was set for Oct. 7 to decide whether the lawsuit should be converted to a nationwide class-action.

The ads also said "Paxil has been studied both in short-term and long-term use and is not associated with dependence and addiction."

Surging U.S. sales of Paxil and the asthma drug Advair led a 15 percent increase in second-quarter profits for London-based GlaxoSmithKline PLC. Global sales of Paxil grew 29 percent.

© MMII The Associated Press. All Rights Reserved. This material may not be published, broadcast, rewritten, or redistributed.




Back to Top Back To Top


• Help  • Advertise  • Feedback  • Terms of Service  • Privacy  • CBS News Bios
©MMIII, CBS Broadcasting Inc. All Rights Reserved.
CBSNews.com


• Interactives
• Early Show: Health News
• Early Show: Shape Up
• Early Show: Emily Senay
Eye On Health
Enter
Explore health issues including AIDS, cancer and antibiotics.

Story  Story Go

Quit Smoking, Cheer Up, Lose Weight
Story  Story Go

Viagra For Kids
Story  Story Go

Alzheimer's Help From Cholesterol Drug?
Story  Story Go

Rape Drug Gets OK To Treat Narcolepsy
Story  Story Go

Generic Prozac In Stores Next Year
Story  Story Go

Lifting Depression at a Lower Price: Prozac Goes Generic
Story  Story Go

Study: St. John's Won't Cure Big Blues







All Broadcasts
The Early Show 
CBS Evening News 
48 Hours 
60 Minutes 
60 Minutes II 
The Sat. Early Show 
Sunday Morning 
Face The Nation 
CBS Morning News 
Up To The Minute 
close [x]